Coronary Intervention & Surgery

At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.
Two hospitals in East Africa have announced participation in the American College of Cardiology’s CathPCI registry, which aims to assess treatments and outcomes related to cardiac catheterization and percutaneous coronary interventions (PCIs).
Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.
Saphenous vein graft (SVG) lesions can be treated just as well with bare metal stents (BMS) as drug-eluting stents (DES), suggests a double-blind, randomized trial published May 11 in The Lancet.
Left radial access (LRA) for percutaneous coronary intervention (PCI) remains rare in the United Kingdom, according to a registry analysis—but it is associated with similar clinical outcomes as right radial access (RRA) and possibly a reduced risk of stroke.
The investigators of the anticipated ISCHEMIA trial have published a paper in Circulation: Cardiovascular Quality and Outcomes defending their late addition of “softer” outcomes to their primary composite endpoint.
Using data from the randomized COURAGE trial, a team of researchers developed a model to predict one-year angina and quality-of-life outcomes among patients with stable coronary artery disease (CAD).
Preliminary research presented May 11 at the American Heart Association’s Vascular Discovery: From Genes to Medicine Scientific Sessions 2018, suggests an injection may one day be able to reverse atherosclerosis.
Each 50-meter increase in a six-minute walk test was associated with 20 percent lower odds of developing cognitive dysfunction after cardiac surgery, according to a single-center study from Japan published in The Annals of Thoracic Surgery.
Requiring hospitals and physicians to publicly report their mortality outcomes related to percutaneous coronary intervention (PCI) causes many interventional cardiologists to forego high-risk procedures, researchers reported in JAMA Cardiology.
A four-step protocol designed to improve care for all patients who experience ST-segment elevation myocardial infarction (STEMI) also reduced gender-specific disparities in suboptimal care and clinical outcomes, Cleveland Clinic researchers reported in the Journal of the American College of Cardiology.
United States veterans receiving invasive coronary procedures have become older and sicker over the past several years, but adjusted mortality rates for percutaneous coronary intervention (PCI) are in a slight decline.
New research published in JACC: Cardiovascular Interventions shows substantial variation between states for non-acute coronary angiograms, percutaneous coronary interventions and coronary artery bypass graft surgeries.
Abbott’s XIENCE Sierra, the newest generation of the company’s everolimus-eluting coronary stent, has been approved for national reimbursement in Japan.
May 01, 2018 | Healthcare Economics
New research suggests people exhibiting ST-segment elevation myocardial infarction (STEMI) receive life-saving treatment more quickly if they live in states that allow emergency medical services (EMS) to take patients straight to hospitals that offer specialized treatment, rather than those that do not.
A meta-analysis published April 30 in the New England Journal of Medicine supports radial artery grafts over saphenous vein grafts in coronary artery bypass surgery (CABG), showing lower risks for myocardial infarction, repeat revascularization and graft occlusion.
With the opioid epidemic in full swing and many intravenous drug users likely to relapse and require even more challenging and expensive treatment, physicians are left to grapple with what to do about repeat cases of infective endocarditis.
Operators trained in the hybrid approach to PCI of chronic total occlusions (CTOs) demonstrated technical and procedural success rates of 87 percent and 85 percent, respectively, in a multicenter international trial.
A new meta-analysis found double antithrombotic therapy following PCI for patients with atrial fibrillation (AFib) was associated with 47 percent fewer bleeding events than triple therapy and similar rates of major adverse cardiac events.
A retrospective study of patients with acute MI complicated by cardiogenic shock presented at SCAI 2018 supported the message from the randomized CULPRIT-SHOCK trial: culprit lesion PCI is associated with lower mortality than multivessel revascularization.
Individuals who receive surgical aortic valve replacement (SAVR) within three months of an ischemic stroke are almost 15 times more likely to suffer another stroke than SAVR patients without previous strokes, according to a Danish registry study published April 25 in JAMA Cardiology.